Attention, inhalers may increase the risk of death

Inhalers are designed to help people with chronic bronchitis and emphysema to breathe easier and avoid the risk of death due to shortness of breath. However, the use of inhalers in the long term can in fact increase the risk of death.

The results were disclosed in the British Medical Journal recently. The research was conducted by scientists from the University of East Anglia and three American universities. It was mentioned that the use of Tiotropiun Respimat (also known as the Sprivia Respimat), substance to make inhalers, could increase the risk of death by more than 50%.

In Britain, chronic bronchitis and emphysema were attacked three million people and caused 24 of thousands of deaths in 2005. People with pulmonary disease Obstructive chronic (COPD), a term for people with chronic bronchitis and emphysema, mainly used inhalers to help breathing. Use in 2010 showed that more than a million people have been prescribed inhalers Tiotropium.

Tiotropium inhalers are available internationally for some years previously. Tiotropium for Respimat inhaler was launched recently and its products are used in the United Kingdom and in Europe. However, the Food and Drug Administration/FDA cannot guarantee the use of Tiotropium Respimat in America because they believe it needs additional tests.

"We analyzed five clinical trials of 6,500 people." "And the risk of death in patients who use this type of inhalers reached 52 per cent higher," said Dr. Yoon Loke Norwich Medical School, University of East Anglia, according to the Madicalnewstoday.

Yoon Loke said, estimates of the Institute there is a further death in each 124 patients taking Respimat Tiotropium for one year. Some of these risks arise from patients who die because of the disorder of the heart pace because of the potential for adverse effects of Tiotropium.

Loke and his colleagues of America considered the risk of Tiotropium Respimat inhaler after analyzing the data presented in the document of the FDA, they concluded that there is a clear indication of the increase in the risk of mortality, particularly those related to heart problems.

Since then, we found that, for security reasons, Tiotropium Respimat is not guaranteed FDA for use in America,"said Loke.

Loke said there is an alternative to inhalers that can be used by people with chronic bronchitis and emphysema. Patients who already use Tiotropium Respimat not must stop the appliance suddenly, but should always consult a physician for the possibility of replacing it with a different recipe. Then, since Respimat of Tiotropium may cause the opposite effect on heart rate, patients with a history of arrhythmia should also be wary of this type of inhalers.